SARS-CoV-2 Test Information I am a: United States (English) Request Info Tests Systems Impact Education Support About Us Enabling Global Health Solutions With the increasing popularity of the GeneXpert® System, as well as the technology’s enormous potential to facilitate the diagnosis of multiple diseases in individual patients, Cepheid recognizes its responsibility in continuing critical test development and enabling platform access beyond the traditional laboratory. A Global Need For Better Choices Globally, these are mission-critical for Cepheid as a leading diagnostics company — because control of worldwide health threats may be hampered when testing is performed only in centralized labs, far from where patients live. Patients often travel long distances for diagnostic testing, or their samples must be transported — which may delay test results and impact patient care. Moreover, test results may get lost or never make it back to the patients. A Mission to Deliver Progress to Everyone Decentralization of testing facilities increases access and improves outcomes, as shown by recent studies from countries like Malawi1, where infants were tested for HIV both immediately at the point of care and by sending samples to a remote laboratory. More results were delivered to clinicians and more babies treated when tested locally. The more than 10,000 GeneXpert Systems that have been installed in low and middle-income countries2, mainly for the diagnosis of active tuberculosis, can also be used to test for the nearly 30 CE-IVD3 Xpert tests now available. Outcomes That Speak For Themselves Global health organizations, countries, donors and other stakeholders have been encouraging and supporting the more integrated, efficient use of diagnostics to work toward WHO targets for eliminating diseases such as HIV, tuberculosis, HCV and cervical cancer. "Unitaid has made significant investments in advancing integration in molecular diagnostics. Integrating care means more people healed, more lives saved, more efficient use of resources," Unitaid Executive Director Lelio Marmora said. "Now we need manufacturers to share in the responsibility of making sure these technologies work seamlessly in countries as part of sustainable systems." VIDEO ZDoggMD Discusses Tuberculosis with Cepheid CMO Dr. Dave Persing Each day, nearly 4,500 people lose their lives to TB and close to 30,000 people fall ill. ZDoggMD and Dr. Persing discuss the global impact of a fast and accurate TB test that also detects drug resistance in the United States and globally. Watch Video Resources WEBPAGE Global Access - HBDC Program PRODUCT 1. Mwenda et al. Significantly improved antiretroviral therapy initiation rates after implementation of Point of Care Early Infant Diagnosis. ASLM 2016 2. HBDC Access Program covers 130 Low and Middle-income countries. Conditions can be found on the FIND website (https://www.finddx.org/find-negotiated-product-pricing/) 3. Some products not available in the US QUICK LINKS About Us Careers Contact Us Distributors Package Inserts Laboratory Professionals Healthcare Professionals Healthcare Administrators LEGAL AdvaMed Code of Ethics Privacy Trademarks Terms of Use Product Security Updates Do Not Sell My Personal Information Cookies Settings ©2021 Cepheid. All Rights Reserved. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy Cookies Settings Reject Accept